secwatch.observer — SEC 8-K summary
======================================

Issuer:     LISATA THERAPEUTICS, INC. (LSTA)
CIK:        0000320017
Form:       8-K
Filed at:   2022-08-19T23:59:59+00:00
Accession:  0000320017-22-000071
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Caladrius receives Nasdaq extension to Feb 13, 2023 to regain $1 bid price compliance
--------------------------------------------------------------------------------

- Company failed to meet $1 minimum bid price by Aug 17, 2022 initial compliance deadline.
- Nasdaq granted extension to Feb 13, 2023; requires closing bid of $1+ for 10 consecutive days.
- If compliance not demonstrated by Feb 13, 2023, delisting notice will be issued.
- Company may appeal delisting determination, but success cannot be assured.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/320017/000032001722000071/0000320017-22-000071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/320017/000032001722000071/clbs-20220818.htm
  HTML page:      https://secwatch.observer/filing/0000320017-22-000071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer